These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20404640)

  • 21. Impact of levosimendan on platelet function.
    Sikora J; Pstrągowski K; Skibińska N; Sobczak P; Sikora A; Marszałł MP; Fabiszak T; Grześk G; Kubica J
    Thromb Res; 2017 Nov; 159():76-81. PubMed ID: 28987709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levosimendan as rescue therapy in severe cardiogenic shock after ST-elevation myocardial infarction.
    Greif M; Zwermann L; Reithmann C; Weis M
    Acute Card Care; 2008; 10(3):185-90. PubMed ID: 18972629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levosimendan in cardiac surgery: a unique drug for the treatment of perioperative left ventricular dysfunction or just another inodilator searching for a clinical application?
    Pagel PS
    Anesth Analg; 2007 Apr; 104(4):759-61. PubMed ID: 17377077
    [No Abstract]   [Full Text] [Related]  

  • 24. Evidence-based use of levosimendan in different clinical settings.
    De Luca L; Colucci WS; Nieminen MS; Massie BM; Gheorghiade M
    Eur Heart J; 2006 Aug; 27(16):1908-20. PubMed ID: 16682381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Levosimendan: calcium sensitizer and inodilator.
    Milligan DJ; Fields AM
    Anesthesiol Clin; 2010 Dec; 28(4):753-60. PubMed ID: 21074750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decongestive effects of levosimendan in cardiogenic shock induced by postpartum cardiomyopathy.
    Labbene I; Arrigo M; Tavares M; Hajjej Z; Brandão JL; Tolppanen H; Feliot E; Gayat E; Ferjani M; Mebazaa A
    Anaesth Crit Care Pain Med; 2017 Feb; 36(1):39-42. PubMed ID: 27436451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levosimendan in perioperative and critical care patients.
    Salmenperä M; Eriksson H
    Curr Opin Anaesthesiol; 2009 Aug; 22(4):496-501. PubMed ID: 19502977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levosimendan as a treatment for acute renal failure associated with cardiogenic shock after hip fracture.
    Hinojosa FQ; Revelo M; Salazar A; Maggi G; Schiraldi R; Brogly N; Gilsanz F
    Braz J Anesthesiol; 2017; 67(1):89-91. PubMed ID: 28017176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of levosimendan for treatment of cardiogenic shock associated with electrical storm.
    Grazi M; Lauri G; Carbucicchio C; Marenzi G
    Ann Intern Med; 2009 May; 150(10):738-40. PubMed ID: 19451590
    [No Abstract]   [Full Text] [Related]  

  • 31. The effects of Levosimendan on global haemodynamics in patients with cardiogenic shock.
    Rokyta R; Pechman V
    Neuro Endocrinol Lett; 2006; 27(1-2):121-7. PubMed ID: 16648778
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levosimendan in cardiogenic shock: better than enoximone!
    Buerke M; Prondzinsky R
    Crit Care Med; 2008 Aug; 36(8):2450-1. PubMed ID: 18664796
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of levosimendan on the energy balance: preclinical and clinical evidence.
    Nieminen MS; Pollesello P; Vajda G; Papp Z
    J Cardiovasc Pharmacol; 2009 Apr; 53(4):302-10. PubMed ID: 19276987
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Misinterpretation of the sublingual microcirculation during therapy with levosimendan.
    Hessler M; Arnemann PH; Rehberg S; Ertmer C
    Clin Hemorheol Microcirc; 2018; 68(1):83-87. PubMed ID: 29036801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levosimendan or enoximone in refractory cardiogenic shock?
    Berthelsen PG
    Crit Care Med; 2009 Mar; 37(3):1182. PubMed ID: 19237971
    [No Abstract]   [Full Text] [Related]  

  • 36. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM; Akhter MW
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction.
    Beute J
    Crit Care Med; 2009 Sep; 37(9):2678; author reply 2678-9. PubMed ID: 19687655
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy of levosimendan in Takotsubo-related cardiogenic shock.
    Antonini M; Stazi GV; Cirasa MT; Garotto G; Frustaci A
    Acta Anaesthesiol Scand; 2010 Jan; 54(1):119-20. PubMed ID: 19961441
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.